HilleVax reports Q1 EPS (12c) vs (97c) last year

Written by Emily J. Thompson, Senior Investment Analyst

HLVX%

Updated: May 08 2025

0mins

Financial Overview: As of March 31, 2025, the company reported cash and marketable securities totaling $159.5 million, down from $171.4 million on December 31, 2024.
R&D Expenses: Research and development expenses significantly decreased to $2.0 million in Q1 2025 from $26.0 million in Q1 2024, primarily due to reduced clinical development costs.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

HilleVax reports Q1 EPS (12c) vs (97c) last year

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Amazon vs. Walmart: A Battle of Growth and Logistics

Warren Buffett Recommends Vanguard ETF Portfolio: 90% in S&P 500

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch